Details for Patent: 10,105,444
Which drugs does patent 10,105,444 protect, and when does it expire?
Patent 10,105,444 protects JUBLIA and is included in one NDA.
Summary for Patent: 10,105,444
| Title: | Compositions and methods for treating diseases of the nail |
| Abstract: | Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, which composition has a surface tension of 40 dynes/cm or less and has continuing spreadability, and which composition is effective in treating a disorder of the nail or nail bed. |
| Inventor(s): | Gareth Winckle, Gregory T. Fieldson |
| Assignee: | Dow Pharmaceutical Sciences Inc |
| Application Number: | US15/826,109 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,105,444 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Delivery; |
Drugs Protected by US Patent 10,105,444
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | JUBLIA | efinaconazole | SOLUTION;TOPICAL | 203567-001 | Jun 6, 2014 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
